Connective tissue growth factor promotes articular damage by increased osteoclastogenesis in patients with rheumatoid arthritis

Arthritis Research and Therapy

Volumn 11, Issue 6, 2009, Pages

  Nozawa, Kazuhisa ^a,b   Fujishiro, Maki ^a   Kawasaki, Mikiko ^a   Kaneko, Hiroshi ^b   Iwabuchi, Kazuhisa ^a   Yanagida, Mitsuaki ^a   Suzuki, Fujihiko ^b   Miyazawa, Keiji ^c   Takasaki, Yoshinari ^d   Ogawa, Hideoki ^a   Takamori, Kenji ^a   Sekigawa, Iwao ^a,b  

^a JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY URAYASU HOSPITAL   (Japan)

^c KISSEI PHARMACEUTICAL CO LTD   (Japan)

^d JUNTENDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; C REACTIVE PROTEIN; COLONY STIMULATING FACTOR 1; CONNECTIVE TISSUE GROWTH FACTOR; FOCAL ADHESION KINASE; GROWTH FACTOR RECEPTOR; INFLIXIMAB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OSTEOCLAST DIFFERENTIATION FACTOR; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; VITRONECTIN RECEPTOR; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ARTHROPATHY; ARTICLE; BLOOD SAMPLING; CARTILAGE CELL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SYNTHESIS; ERYTHROCYTE SEDIMENTATION RATE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; NUCLEOTIDE SEQUENCE; OSTEOARTHROPATHY; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; PATHOGENESIS; PROTEIN SYNTHESIS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYNOVIOCYTE; SYSTEMIC LUPUS ERYTHEMATOSUS; CELL DIFFERENTIATION; CYTOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOPRECIPITATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOTTING, WESTERN; CELL DIFFERENTIATION; CONNECTIVE TISSUE GROWTH FACTOR; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; OSTEOCLASTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77952476189     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2863     Document Type: Article

References (42)

1. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996, 14:397-440. 10.1146/annurev.immunol.14.1.397, 8717520.
2. Fassbender HG, Seibel M, Hebert T. Pathways of destruction in metacarpal and metatarsal joints of patients with rheumatoid arthritis. Scand J Rheumatol 1992, 21:10-16. 10.3109/03009749209095055, 1570480.
3. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005, 115:3318-3325. 10.1172/JCI27071, 1297264, 16322775.
4. Teitelbaum SL. Osteoclasts: what do they do and how do they do it?. Am J Pathol 2007, 170:427-435. 10.2353/ajpath.2007.060834, 1851862, 17255310.
5. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu Rev Immunol 2001, 19:163-196. 10.1146/annurev.immunol.19.1.163, 11244034.
6. Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J. Regulation of serum chemokines following infliximab therapy in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006, 24:529-533.
7. Maini RN, Elliott MJ, Brennan FM, Williams RO, Chu CQ, Paleolog E, Charles PJ, Taylor PC, Feldmann M. Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev 1995, 144:195-223. 10.1111/j.1600-065X.1995.tb00070.x, 7590814.
8. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, Steiner G, Smolen JS, Wagner EF, Schett G. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002, 110:1419-1427. 151809, 12438440.
9. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354:1932-1939. 10.1016/S0140-6736(99)05246-0, 10622295.
10. Sekigawa I, Yanagida M, Iwabuchi K, Kaneda K, Kaneko H, Takasaki Y, Jung G, Sone S, Tanaka Y, Ogawa H, Takamori K. Protein biomarker analysis by mass spectrometry in patients with rheumatoid arthritis receiving anti-tumor necrosis factor-alpha antibody therapy. Clin Exp Rheumatol 2008, 26:261-267.
11. Bradham DM, Igarashi A, Potter RL, Grotendorst GR. Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol 1991, 114:1285-1294. 10.1083/jcb.114.6.1285, 2289134, 1654338.
12. Grotendorst GR. Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev 1997, 8:171-179. 10.1016/S1359-6101(97)00010-5, 9462483.
13. Perbal B. CCN proteins: multifunctional signalling regulators. Lancet 2004, 363:62-64. 10.1016/S0140-6736(03)15172-0, 14723997.
14. Takigawa M, Nakanishi T, Kubota S, Nishida T. Role of CTGF/HCS24/ecogenin in skeletal growth control. J Cell Physiol 2003, 194:256-266. 10.1002/jcp.10206, 12548546.
15. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
16. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH, . European Study Group on Classification Criteria for Sjögren's Syndrome Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002, 61:554-558. 10.1136/ard.61.6.554, 1754137, 12006334, European Study Group on Classification Criteria for Sjögren's Syndrome.
17. Itoh Y, Hayashi H, Miyazawa K, Kojima S, Akahoshi T, Onozaki K. 17beta-estradiol induces IL-1alpha gene expression in rheumatoid fibroblast-like synovial cells through estrogen receptor alpha (ERalpha) and augmentation of transcriptional activity of Sp1 by dissociating histone deacetylase 2 from ERalpha. J Immunol 2007, 178:3059-3066.
18. Shinoda Y, Ogata N, Higashikawa A, Manabe I, Shindo T, Yamada T, Kugimiya F, Ikeda T, Kawamura N, Kawasaki Y, Tsushima K, Takeda N, Nagai R, Hoshi K, Nakamura K, Chung UI, Kawaguchi H. Kruppel-like factor 5 causes cartilage degradation through transactivation of matrix metalloproteinase 9. J Biol Chem 2008, 283:24682-24689. 10.1074/jbc.M709857200, 18617520.
19. Nakao K, Kubota S, Doi H, Eguchi T, Oka M, Fujisawa T, Nishida T, Takigawa M. Collaborative action of M-CSF and CTGF/CCN2 in articular chondrocytes: possible regenerative roles in articular cartilage metabolism. Bone 2005, 36:884-892. 10.1016/j.bone.2004.10.015, 15820145.
20. Murphy MG, Cerchio K, Stoch SA, Gottesdiener K, Wu M, Recker R. Effect of L-00084 an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 2005, 90:2022-2028. 10.1210/jc.2004-2126, 15687321.
21. Chen PS, Wang MY, Wu SN, Su JL, Hong CC, Chuang SE, Chen MW, Hua KT, Wu YL, Cha ST, Babu MS, Chen CN, Lee PH, Chang KJ, Kuo ML. CTGF enhances the motility of breast cancer cells via an integrin-alphavbeta3-ERK1/2-dependent S100A4-upregulated pathway. J Cell Sci 2007, 120:2053-2065. 10.1242/jcs.03460, 17550972.
22. Tan TW, Lai CH, Huang CY, Yang WH, Chen HT, Hsu HC, Fong YC, Tang CH. CTGF enhances migration and MMP-13 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells. J Cell Biochem 2009, 107:345-356. 10.1002/jcb.22132, 19301259.
23. Nakamura I, Duong le T, Rodan SB, Rodan GA. Involvement of alpha(v)beta3 integrins in osteoclast function. J Bone Miner Metab 2007, 25:337-344. 10.1007/s00774-007-0773-9, 17968485.
24. Blaney Davidson EN, Vitters EL, Mooren FM, Oliver N, Berg WB, Kraan PM. Connective tissue growth factor/CCN2 overexpression in mouse synovial lining results in transient fibrosis and cartilage damage. Arthritis Rheum 2006, 54:1653-1661. 10.1002/art.21795, 16646035.
25. Manns JM, Uknis AB, Rico MC, Agelan A, Castaneda J, Arango I, Barbe MF, Safadi FF, Popoff SN, DeLa Cadena RA. A peptide from thrombospondin 1 modulates experimental erosive arthritis by regulating connective tissue growth factor. Arthritis Rheum 2006, 54:2415-2422. 10.1002/art.22021, 16869004.
26. Shimo T, Kubota S, Yoshioka N, Ibaragi S, Isowa S, Eguchi T, Sasaki A, Takigawa M. Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer. J Bone Miner Res 2006, 21:1045-1059. 10.1359/jbmr.060416, 16813525.
27. Schett G. Rheumatoid arthritis: inflammation and bone loss. Wien Med Wochenschr 2006, 156:34-41. 10.1007/s10354-005-0244-7, 16465612.
28. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, Goldring SR. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000, 43:250-258. 10.1002/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO;2-P, 10693863.
29. Shigeyama Y, Pap T, Kunzler P, Simmen BR, Gay RE, Gay S. Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum 2000, 43:2523-2530. 10.1002/1529-0131(200011)43:11<2523::AID-ANR20>3.0.CO;2-Z, 11083276.
30. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ, Takayanagi H. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006, 203:2673-2682. 10.1084/jem.20061775, 2118166, 17088434.
31. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000, 106:1481-1488. 10.1172/JCI11176, 387259, 11120755.
32. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005, 115:282-290. 544608, 15668736.
33. Lipsky PE, Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN, . Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000, 343:1594-1602. 10.1056/NEJM200011303432202, 11096166, Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
34. Smolen JS, Han C, Bala M, Maini RN, Kalden JR, Heijde D, Breedveld FC, Furst DE, Lipsky PE. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005, 52:1020-1030. 10.1002/art.20982, 15818697.
35. Leung JC, Chan LY, Tam KY, Tang SC, Lam MF, Cheng AS, Chu KM, Lai KN. Regulation of CCN2/CTGF and related cytokines in cultured peritoneal cells under conditions simulating peritoneal dialysis. Nephrol Dial Transplant 2009, 24:458-469. 10.1093/ndt/gfn524, 18805993.
36. Cooker LA, Peterson D, Rambow J, Riser ML, Riser RE, Najmabadi F, Brigstock D, Riser BL. TNF-alpha, but not IFN-gamma, regulates CCN2 (CTGF), collagen type I, and proliferation in mesangial cells: possible roles in the progression of renal fibrosis. Am J Physiol Renal Physiol 2007, 293:F157-165. 10.1152/ajprenal.00508.2006, 17376761.
37. Karger A, Fitzner B, Brock P, Sparmann G, Emmrich J, Liebe S, Jaster R. Molecular insights into connective tissue growth factor action in rat pancreatic stellate cells. Cell Signal 2008, 20:1865-1872. 10.1016/j.cellsig.2008.06.016, 18639630.
38. Yu F, Chou CW, Chen CC. TNF-alpha suppressed TGF-beta-induced CTGF expression by switching the binding preference of p300 from Smad4 to p65. Cell Signal 2009, 21:867-872. 10.1016/j.cellsig.2009.01.030, 19385047.
39. Wehling N, Palmer GD, Pilapil C, Liu F, Wells JW, Muller PE, Evans CH, Porter RM. Interleukin-1beta and tumor necrosis factor alpha inhibit chondrogenesis by human mesenchymal stem cells through NF-kappaB-dependent pathways. Arthritis Rheum 2009, 60:801-812. 10.1002/art.24352, 2688727, 19248089.
40. Polzer K, Schett G, Zwerina J. The lonely death: chondrocyte apoptosis in TNF-induced arthritis. Autoimmunity 2007, 40:333-336. 10.1080/08916930701356721, 17516222.
41. Mun SH, Kim JW, Nah SS, Ko NY, Lee JH, Kim JD, Kim do K, Kim HS, Choi JD, Kim SH, Lee CK, Park SH, Kim BK, Kim HS, Kim YM, Choi WS. Tumor necrosis factor alpha-induced interleukin-32 is positively regulated via the Syk/protein kinase Cdelta/JNK pathway in rheumatoid synovial fibroblasts. Arthritis Rheum 2009, 60:678-685. 10.1002/art.24299, 19248119.
42. Gao B, Calhoun K, Fang D. The proinflammatory cytokines IL-1beta and TNF-alpha induce the expression of Synoviolin, an E3 ubiquitin ligase, in mouse synovial fibroblasts via the Erk1/2-ETS1 pathway. Arthritis Res Ther 2006, 8:R172. 10.1186/ar2081, 1794516, 17105652.